New Insights into the Mechanism of Action of Antipsychotic Drugs
11 3월 2009 - 5:00AM
PR Newswire (US)
ROCKVILLE, Md., March 10 /PRNewswire-FirstCall/ -- Vanda
Pharmaceuticals Inc. (NASDAQ:VNDA) reports the publication in
Schizophrenia Research, the official journal of the Schizophrenia
International Research Society, of a manuscript entitled "Common
effect of antipsychotics on the biosynthesis and regulation of
fatty acids and cholesterol supports a key role of lipid
homeostasis in schizophrenia" (1). This publication highlights the
discovery of a major effect of antipsychotics that sheds new light
on how these drugs work. Vanda researchers analyzed the mechanism
of action of 18 antipsychotics at the molecular level and
discovered that they regulate specific genes that control the
production and transport of lipids. These findings suggest that
antipsychotic drugs may alter the fluidity of cell membranes of
neurons, which could result in changes in neuronal connectivity.
The antipsychotics tested included Vanda's antipsychotic
iloperidone, currently under review by the U.S. Food and Drug
Administration (FDA) for the treatment of schizophrenia. "This
exciting discovery demonstrates Vanda's commitment in understanding
the molecular mechanism of drugs with a goal of improving
therapeutic solutions for patients" said Mihael H. Polymeropoulos,
MD, Vanda's Chief Executive Officer. (1) Polymeropoulos M.H. et
al., "Common effect of antipsychotics on the biosynthesis and
regulation of fatty acids and cholesterol supports a key role of
lipid homeostasis in schizophrenia." Schizophr Res. 2009 Mar;
108(1-3):134-42. About Vanda Pharmaceuticals Inc.: Vanda
Pharmaceuticals Inc. is a biopharmaceutical company focused on the
development and commercialization of clinical-stage product
candidates for central nervous system disorders. For more on Vanda
Pharmaceuticals Inc., please visit http://www.vandapharma.com/.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Various
statements in this release are "forward-looking statements" under
the securities laws. Words such as, but not limited to, "believe,"
"expect," "anticipate," "estimate," "intend," "plan," "targets,"
"likely," "will," "would," and "could," and similar expressions or
words, identify forward-looking statements. Forward-looking
statements are based upon current expectations that involve risks,
changes in circumstances, assumptions and uncertainties. Vanda is
at an early stage of development and may not ever have any products
that generate significant revenue. Important factors that could
cause actual results to differ materially from those reflected in
the company's forward-looking statements include, among others:
delays in the completion of Vanda's clinical trials; a failure of
Vanda's product candidates to be demonstrably safe and effective;
Vanda's failure to obtain regulatory approval for its products or
to comply with ongoing regulatory requirements; a lack of
acceptance of Vanda's product candidates in the marketplace, or a
failure to become or remain profitable; Vanda's inability to obtain
the capital necessary to fund its research and development
activities; Vanda's failure to identify or obtain rights to new
product candidates; Vanda's failure to develop or obtain sales,
marketing and distribution resources and expertise or to otherwise
manage its growth; a loss of any of Vanda's key scientists or
management personnel; losses incurred from product liability claims
made against Vanda; a loss of rights to develop and commercialize
Vanda's products under its license and sublicense agreements and
other factors that are described in the "Risk Factors" section
(Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the
quarter ended September 30, 2008 (File No. 000-51863). In addition
to the risks described above and in Part II, Item 1A of Vanda's
quarterly report on Form 10-Q, other unknown or unpredictable
factors also could affect Vanda's results. There can be no
assurance that the actual results or developments anticipated by
Vanda will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, Vanda.
Therefore, no assurance can be given that the outcomes stated in
such forward-looking statements and estimates will be achieved. All
written and verbal forward-looking statements attributable to Vanda
or any person acting on its behalf are expressly qualified in their
entirety by the cautionary statements contained or referred to
herein. Vanda cautions investors not to rely too heavily on the
forward-looking statements Vanda makes or that are made on its
behalf. The information in this release is provided only as of the
date of this release, and Vanda undertakes no obligation, and
specifically declines any obligation, to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Vanda
Pharmaceuticals Inc. CONTACT: Stephanie R. Irish, Acting Chief
Financial Officer of Vanda Pharmaceuticals Inc., +1-240-599-4500
Web Site: http://www.vandapharma.com/
Copyright
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024